Clinical Trials Logo

Drug Hypersensitivity clinical trials

View clinical trials related to Drug Hypersensitivity.

Filter by:

NCT ID: NCT06428162 Active, not recruiting - Drug Abuse Clinical Trials

a Cross-sectional Study of Pharmacovigilance Practices Adherence Between Healthcare Providers in North African Nation

Start date: February 18, 2024
Phase:
Study type: Observational

a predesignated survey about information on drug adverse events and pharmacovigilance role in detection and reporting was distributed in different regions (urban/rural/mixed) in Egypt. the survey composed of three sections; demographics, person reported or not reported and was directed for health care providers to study their awareness about pharmacovigilance cores and its practices. additionally the survey included further questions about reported adverse events.

NCT ID: NCT06414694 Enrolling by invitation - Drug Allergy Clinical Trials

Inpatient Penicillin Delabeling for Low-Risk Patients

Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

This study seeks to enroll patients admitted to a children's hospital with identified penicillin allergy. A screening checklist is performed to identify patients with very low or low risk histories of penicillin allergy to offer direct oral challenges to the antibiotic class to de-label patient's with drug allergies.

NCT ID: NCT06409884 Not yet recruiting - Amoxicillin Allergy Clinical Trials

Diagnosing Drug Allergy: the T is the Key

TAT
Start date: May 25, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.

NCT ID: NCT06406114 Not yet recruiting - Clinical trials for Drug Hypersensitivity

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

DACAT
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

NCT ID: NCT06399601 Not yet recruiting - Drug Allergy Clinical Trials

A Training Program of Drug Allergy for Healthcare Professionals

Start date: December 9, 2024
Phase: N/A
Study type: Interventional

Drug allergy is often under-recognized, yet over- (mistakenly) diagnosed, especially in Hong Kong. There is also a dire shortage of allergy specialists and facilities to tackle the overwhelming drug allergy pandemic. Fortunately, when trained, non-specialist physicians and nurses have demonstrated comparable capabilities in drug allergy evaluation compared to specialists. To potentially promote and propagate the role of non-specialist physicians and nurses toward drug allergy care, the investigators propose a study to investigate the impact of an intensive and focused drug allergy educational course conducted at the University of Hong Kong.

NCT ID: NCT06303128 Recruiting - Penicillin Allergy Clinical Trials

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

Start date: February 3, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about dosing when testing to see if a penicillin allergy label can be removed from adults that had been labeled as "penicillin-allergic" previously. The main question it aims to answer is: - In penicillin-allergic patients that are at low risk of having an allergic reaction, is a one-dose oral challenge with amoxicillin (a penicillin-based antibiotic) as safe and effective as a two-dose oral challenge? Participants will, after being identified as having a low-risk penicillin allergy, be administered oral amoxicillin in a controlled setting and then monitored for an allergic reaction. Researchers will compare participants that took one dose of amoxicillin to participants that took two doses of amoxicillin (a small dose and then a larger dose) to see if either group was more likely to develop an allergic reaction.

NCT ID: NCT06263140 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study

Start date: May 30, 2021
Phase:
Study type: Observational

Serum vitamin D levels in drug-induced non-immediate reactions

NCT ID: NCT06112470 Recruiting - Allergy Penicillin Clinical Trials

Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs

ALLMED
Start date: February 28, 2023
Phase:
Study type: Observational

This study focuses on the experience of the military patient reporting a suspected drug allergy, with its own specificities. Suspicions of drug allergies during a mission expose the doctor to difficulties. This study will improve understanding of the allergy patient's point of view. The end result could be a set of ideas for measures to raise awareness among these patients, and motivate them to undergo an allergological assessment.

NCT ID: NCT06067919 Recruiting - Clinical trials for Good Comprehension of French Language

Assessment of the Applicability and Acceptability of an Algorithm to Guide the Prescription of 1st and 2nd Generation Cephalosporins as Part of Intraoperative Antibiotic Prophylaxis in Patients With a Declared Allergy to Penicillin

PROPHYLAL
Start date: October 9, 2023
Phase: N/A
Study type: Interventional

According to the Centers for Disease Control and Prevention (CDC), a surgical site infection (SSI) is an infection that occurs after surgery at the site where the surgery was performed. The prevalence of SSIs is difficult to obtain and is probably underestimated, as many SSIs occur after the patient has been discharged from hospital and are not taken into account. SSIs are responsible for an increase in length of stay, mortality and costs. Their prevention is therefore essential in the operating theater, and has been the subject of recommendations recently updated by the CDC. The first line of prevention is the administration of prophylaxis antibiotic adapted to the surgical procedure, administered within a specific timeframe in order to achieve an effective bactericidal concentration in the tissues at the time of the surgical incision. In France, in the United States and for the WHO, the recommended first line of antibiotic prophylaxis is most often an agent from the beta-lactam family, a penicillin or a cephalosporin, with the exception of ophthalmological surgery. No strategy is described for the management of patients with a reported allergy to penicillin, apart from the recommendation of therapeutic alternatives. The use of a decision-making strategy in the operating theater for patients with a reported allergy to penicillin therefore appears necessary and is recommended by experts. In the intraoperative context, the application of a strategy would make it possible to guide the use of cephalosporins, without removing the "penicillin allergy" label from the patient, but by proposing an alternative via the use of a cephalosporin depending on the probability of the risk of a real allergy to penicillin, according to the description of the former reaction.

NCT ID: NCT06065137 Recruiting - Hypersensitivity Clinical Trials

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

Start date: October 23, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and outcome of systematic drug provocation testing with anaesthetics at therapeutic doses in adult patients undergoing diagnostic work-up for perioperative hypersensitivity.